Definitions of the phenotypic manifestations of sickle cell disease

Samir K. Ballas, Susan Lieff, Lennette J. Benjamin, Carlton D. Dampier, Matthew M. Heeney, Carolyn Hoppe, Cage S. Johnson, Zora R. Rogers, Kim Smith-Whitley, Winfred C. Wang, Marilyn J. Telen

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Sickle cell disease (SCD) is a pleiotropic genetic disorder of hemoglobin that has profound multiorgan effects. The low prevalence of SCD (∼100,000/US) has limited progress in clinical, basic, and translational research. Lack of a large, readily accessible population for clinical studies has contributed to the absence of standard definitions and diagnostic criteria for the numerous complications of SCD and inadequate understanding of SCD pathophysiology. In 2005, the Comprehensive Sickle Cell Centers initiated a project to establish consensus definitions of the most frequently occurring complications. A group of clinicians and scientists with extensive expertise in research and treatment of SCD gathered to identify and categorize the most common complications. From this group, a formal writing team was formed that further reviewed the literature, sought specialist input, and produced definitions in a standard format. This article provides an overview of the process and describes 12 body system categories and the most prevalent or severe complications within these categories. A detailed Appendix provides standardized definitions for all complications identified within each system. This report proposes use of these definitions for studies of SCD complications, so future studies can be comparably robust and treatment efficacy measured. Use of these definitions will support greater accuracy in genotype-phenotype studies, thereby achieving a better understanding of SCD pathophysiology. This should nevertheless be viewed as a dynamic rather than final document; phenotype descriptions should be reevaluated and revised periodically to provide the most current standard definitions as etiologic factors are better understood, and new diagnostic options are developed.

Original languageEnglish (US)
Pages (from-to)6-13
Number of pages8
JournalAmerican Journal of Hematology
Volume85
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Sickle Cell Anemia
Phenotype
Inborn Genetic Diseases
Translational Medical Research
Hemoglobins
Genotype
Research
Population

ASJC Scopus subject areas

  • Hematology

Cite this

Ballas, S. K., Lieff, S., Benjamin, L. J., Dampier, C. D., Heeney, M. M., Hoppe, C., ... Telen, M. J. (2010). Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology, 85(1), 6-13. https://doi.org/10.1002/ajh.21550

Definitions of the phenotypic manifestations of sickle cell disease. / Ballas, Samir K.; Lieff, Susan; Benjamin, Lennette J.; Dampier, Carlton D.; Heeney, Matthew M.; Hoppe, Carolyn; Johnson, Cage S.; Rogers, Zora R.; Smith-Whitley, Kim; Wang, Winfred C.; Telen, Marilyn J.

In: American Journal of Hematology, Vol. 85, No. 1, 01.2010, p. 6-13.

Research output: Contribution to journalArticle

Ballas, SK, Lieff, S, Benjamin, LJ, Dampier, CD, Heeney, MM, Hoppe, C, Johnson, CS, Rogers, ZR, Smith-Whitley, K, Wang, WC & Telen, MJ 2010, 'Definitions of the phenotypic manifestations of sickle cell disease', American Journal of Hematology, vol. 85, no. 1, pp. 6-13. https://doi.org/10.1002/ajh.21550
Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C et al. Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology. 2010 Jan;85(1):6-13. https://doi.org/10.1002/ajh.21550
Ballas, Samir K. ; Lieff, Susan ; Benjamin, Lennette J. ; Dampier, Carlton D. ; Heeney, Matthew M. ; Hoppe, Carolyn ; Johnson, Cage S. ; Rogers, Zora R. ; Smith-Whitley, Kim ; Wang, Winfred C. ; Telen, Marilyn J. / Definitions of the phenotypic manifestations of sickle cell disease. In: American Journal of Hematology. 2010 ; Vol. 85, No. 1. pp. 6-13.
@article{625d74d0f3c244f6a4c5d48981d38ec5,
title = "Definitions of the phenotypic manifestations of sickle cell disease",
abstract = "Sickle cell disease (SCD) is a pleiotropic genetic disorder of hemoglobin that has profound multiorgan effects. The low prevalence of SCD (∼100,000/US) has limited progress in clinical, basic, and translational research. Lack of a large, readily accessible population for clinical studies has contributed to the absence of standard definitions and diagnostic criteria for the numerous complications of SCD and inadequate understanding of SCD pathophysiology. In 2005, the Comprehensive Sickle Cell Centers initiated a project to establish consensus definitions of the most frequently occurring complications. A group of clinicians and scientists with extensive expertise in research and treatment of SCD gathered to identify and categorize the most common complications. From this group, a formal writing team was formed that further reviewed the literature, sought specialist input, and produced definitions in a standard format. This article provides an overview of the process and describes 12 body system categories and the most prevalent or severe complications within these categories. A detailed Appendix provides standardized definitions for all complications identified within each system. This report proposes use of these definitions for studies of SCD complications, so future studies can be comparably robust and treatment efficacy measured. Use of these definitions will support greater accuracy in genotype-phenotype studies, thereby achieving a better understanding of SCD pathophysiology. This should nevertheless be viewed as a dynamic rather than final document; phenotype descriptions should be reevaluated and revised periodically to provide the most current standard definitions as etiologic factors are better understood, and new diagnostic options are developed.",
author = "Ballas, {Samir K.} and Susan Lieff and Benjamin, {Lennette J.} and Dampier, {Carlton D.} and Heeney, {Matthew M.} and Carolyn Hoppe and Johnson, {Cage S.} and Rogers, {Zora R.} and Kim Smith-Whitley and Wang, {Winfred C.} and Telen, {Marilyn J.}",
year = "2010",
month = "1",
doi = "10.1002/ajh.21550",
language = "English (US)",
volume = "85",
pages = "6--13",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Definitions of the phenotypic manifestations of sickle cell disease

AU - Ballas, Samir K.

AU - Lieff, Susan

AU - Benjamin, Lennette J.

AU - Dampier, Carlton D.

AU - Heeney, Matthew M.

AU - Hoppe, Carolyn

AU - Johnson, Cage S.

AU - Rogers, Zora R.

AU - Smith-Whitley, Kim

AU - Wang, Winfred C.

AU - Telen, Marilyn J.

PY - 2010/1

Y1 - 2010/1

N2 - Sickle cell disease (SCD) is a pleiotropic genetic disorder of hemoglobin that has profound multiorgan effects. The low prevalence of SCD (∼100,000/US) has limited progress in clinical, basic, and translational research. Lack of a large, readily accessible population for clinical studies has contributed to the absence of standard definitions and diagnostic criteria for the numerous complications of SCD and inadequate understanding of SCD pathophysiology. In 2005, the Comprehensive Sickle Cell Centers initiated a project to establish consensus definitions of the most frequently occurring complications. A group of clinicians and scientists with extensive expertise in research and treatment of SCD gathered to identify and categorize the most common complications. From this group, a formal writing team was formed that further reviewed the literature, sought specialist input, and produced definitions in a standard format. This article provides an overview of the process and describes 12 body system categories and the most prevalent or severe complications within these categories. A detailed Appendix provides standardized definitions for all complications identified within each system. This report proposes use of these definitions for studies of SCD complications, so future studies can be comparably robust and treatment efficacy measured. Use of these definitions will support greater accuracy in genotype-phenotype studies, thereby achieving a better understanding of SCD pathophysiology. This should nevertheless be viewed as a dynamic rather than final document; phenotype descriptions should be reevaluated and revised periodically to provide the most current standard definitions as etiologic factors are better understood, and new diagnostic options are developed.

AB - Sickle cell disease (SCD) is a pleiotropic genetic disorder of hemoglobin that has profound multiorgan effects. The low prevalence of SCD (∼100,000/US) has limited progress in clinical, basic, and translational research. Lack of a large, readily accessible population for clinical studies has contributed to the absence of standard definitions and diagnostic criteria for the numerous complications of SCD and inadequate understanding of SCD pathophysiology. In 2005, the Comprehensive Sickle Cell Centers initiated a project to establish consensus definitions of the most frequently occurring complications. A group of clinicians and scientists with extensive expertise in research and treatment of SCD gathered to identify and categorize the most common complications. From this group, a formal writing team was formed that further reviewed the literature, sought specialist input, and produced definitions in a standard format. This article provides an overview of the process and describes 12 body system categories and the most prevalent or severe complications within these categories. A detailed Appendix provides standardized definitions for all complications identified within each system. This report proposes use of these definitions for studies of SCD complications, so future studies can be comparably robust and treatment efficacy measured. Use of these definitions will support greater accuracy in genotype-phenotype studies, thereby achieving a better understanding of SCD pathophysiology. This should nevertheless be viewed as a dynamic rather than final document; phenotype descriptions should be reevaluated and revised periodically to provide the most current standard definitions as etiologic factors are better understood, and new diagnostic options are developed.

UR - http://www.scopus.com/inward/record.url?scp=74049123836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049123836&partnerID=8YFLogxK

U2 - 10.1002/ajh.21550

DO - 10.1002/ajh.21550

M3 - Article

VL - 85

SP - 6

EP - 13

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -